Literature DB >> 21507185

Dramatic increase in prostate cancer cases by 2021.

Harvey Quon1, Andrew Loblaw, Robert Nam.   

Abstract

UNLABELLED: What's known on the subject? and What does the study add? Estimates of prostate cancer cases are often based solely on changes in the age distribution of the population or on historical trends. This study also incorporates changes in screening prevalence, sensitivity screening maneuvers and lowering threshold for biopsies.
OBJECTIVE: • To estimate the magnitude of increase in prostate cancer cases diagnosed in Canada by the year 2021. PATIENTS AND METHODS: • Using available evidence, the number of new prostate cancer cases expected in 2021 was estimated based on the effects of four major factors: aging population, increased prevalence of PSA screening, lowered PSA cutoff to recommend biopsy, and improved sensitivity of prostate biopsy. • These effects were combined with population data from Statistics Canada and the Canadian Cancer Statistics to estimate new prostate cancer cases.
RESULTS: • The two factors with the largest effect on estimated new prostate cancers in 2021 compared with 2009 were: aging population (increase of 39%), and lowering the PSA threshold to 2.6 ng/mL before prostate biopsy (increase of 200%). • In the 'best-case' scenario, the number of new prostate cancers will only be affected by the aging population and will increase by 39% to 35,121 new cases. • In the 'most-likely' scenario, all four factors will have a combined effect to increase new cases by 201% to 76,379.
CONCLUSIONS: • The aging population and lowering PSA threshold to 2.6 ng/mL have the most significant impact on estimated new prostate cancer cases in 2021. At that time, the number of new cases may triple to 76,379 cases in Canada. • Significant planning will be required to manage this considerable increase in new prostate cancers. .
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21507185     DOI: 10.1111/j.1464-410X.2011.10197.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  19 in total

Review 1.  High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer.

Authors:  A Challapalli; E Jones; C Harvey; G O Hellawell; S A Mangar
Journal:  Br J Radiol       Date:  2012-11       Impact factor: 3.039

2.  Prediction of cancer incidence in Tyrol/Austria for year of diagnosis 2020.

Authors:  Willi Oberaigner; Sabine Geiger-Gritsch
Journal:  Wien Klin Wochenschr       Date:  2014-09-06       Impact factor: 1.704

Review 3.  The endocannabinoid system in prostate cancer.

Authors:  Inés Díaz-Laviada
Journal:  Nat Rev Urol       Date:  2011-09-13       Impact factor: 14.432

4.  Direct cost for initial management of prostate cancer: a systematic review.

Authors:  C Sanyal; A G Aprikian; S Chevalier; F L Cury; A Dragomir
Journal:  Curr Oncol       Date:  2013-12       Impact factor: 3.677

5.  Dietary Pterostilbene for MTA1-Targeted Interception in High-Risk Premalignant Prostate Cancer.

Authors:  Rutu Hemani; Ishani Patel; Ninad Inamdar; Gisella Campanelli; Virginia Donovan; Avinash Kumar; Anait S Levenson
Journal:  Cancer Prev Res (Phila)       Date:  2021-10-21

6.  Projections of cancer prevalence by phase of care: a potential tool for planning future health service needs.

Authors:  Xue Qin Yu; Mark Clements; Dianne O'Connell
Journal:  J Cancer Surviv       Date:  2013-08-07       Impact factor: 4.442

7.  Improved wait time intervals for prostate cancer patients in a multidisciplinary rapid diagnostic unit compared to a community-based referral pattern.

Authors:  Perakaa Sethukavalan; Liying Zhang; Vibhuti Jethava; Christiaan Stevens; Stanley Flax; Roger Buckley; Susan Bondy; Andrew Loblaw
Journal:  Can Urol Assoc J       Date:  2013 Jul-Aug       Impact factor: 1.862

8.  Diagnosis, referral, and primary treatment decisions in newly diagnosed prostate cancer patients in a multidisciplinary diagnostic assessment program.

Authors:  David Guy; Gabriella Ghanem; Andrew Loblaw; Roger Buckley; Beverly Persaud; Patrick Cheung; Hans Chung; Cyril Danjoux; Gerard Morton; Jeff Noakes; Les Spevack; David Hajek; Stanley Flax
Journal:  Can Urol Assoc J       Date:  2016 Mar-Apr       Impact factor: 1.862

9.  Piperine, a Bioactive Component of Pepper Spice Exerts Therapeutic Effects on Androgen Dependent and Androgen Independent Prostate Cancer Cells.

Authors:  Abhilash Samykutty; Aditya Vittal Shetty; Gajalakshmi Dakshinamoorthy; Mary Margaret Bartik; Gary Leon Johnson; Brian Webb; Guoxing Zheng; Aoshuang Chen; Ramaswamy Kalyanasundaram; Gnanasekar Munirathinam
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

10.  Excessive waitlists and delays to treatment with low-dose-rate brachytherapy predict an increased risk of recurrence and metastases in intermediate-risk prostatic carcinoma.

Authors:  Rutvij A Khanolkar; Harvey Quon; Kundan Thind; Michael Sia; Michael Roumeliotis; Siraj Husain; Philip McGeachy; Tyler Meyer; Kevin Martell
Journal:  Clin Transl Radiat Oncol       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.